雾化器市场

2024 年雾化器市值为 8.6646 亿美元，预计到 2031 年将达到 13.1557 亿美元；预计 2025-2031 年期间的复合年增长率将达到 6.2%。市场洞察与分析师观点：对雾化器市场的预测是基于从各种二手和一手研究来源收集的见解。

雾化器是一种用于管理药物的设备，有助于缓解喘息等呼吸系统疾病，并帮助清除肺部分泌物。它将液体药物转化为细小的雾滴，透过面罩或吸嘴吸入，使药物直接进入肺部。与其他吸入器不同，雾化器使用由墙壁插座供电的空气压缩机。

影响雾化器市场成长的驱动因素和限制因素近年来，由于技术进步和产品小型化，家用医疗保健设备日益普及。这一趋势推动了家用医疗保健设备的普及。此外，老龄人口的增加、慢性呼吸系统疾病 (CRD) 的高发病率以及不断上涨的医疗成本，促使人们越来越倾向于选择家庭护理治疗。由于紧凑、便携、用户友好的家用雾化器，以及旨在降低噪音和增强功能的技术创新，家庭医疗保健为昂贵的住院治疗提供了一种经济高效的替代方案。此外，多种药物均可雾化给药，包括长效β2-激动剂 (LABA)、长效毒蕈碱受体拮抗剂、类固醇、抗生素和黏液溶解剂。近期推出的家用产品包括：

2023 年 1 月，Synergy Life Science, Inc. 推出了 Nebi，这是一款由电池供电的紧凑型雾化器，适用于各种应用。 2021 年 7 月，HCmed Innovations 的 Pulmogine 振动网状雾化器获得 FDA 批准，这是一款便携式、用户友好的设备，非常适合需要吸入疗法的患者。 2020 年 6 月，Respira Technologies, Inc. 推出了其 RespiRx 药物输送设备平台，这是一款超便携的手持式振动网状雾化器 (VMN)，设计用于局部和全身治疗各种疾病，包括气喘和 COPD。这些进步将雾化器的应用范围从诊所和医院的急性护理环境扩展到家庭护理环境。

然而，一些因素阻碍了雾化器市场的成长，包括社区对气喘缺乏认知和了解、医疗保健服务有限、医疗系统负担过重、诊断检测（例如肺量计）不足、医护人员培训不足以及气喘管理指南未得到落实。这些问题导致气喘漏诊，导致患者使用不适当的药物治疗，临床疗效不佳，最终预计将阻碍市场成长。儘管全球气喘盛行率不断上升，但人们明显不愿接受传统疗法，因为许多人更喜欢阿育吠陀和家庭疗法。气喘和慢性阻塞性肺病 (COPD) 的治疗指南已发生重大变化，吸入性皮质类固醇 (ICS) 是气喘的一线治疗药物，可单独使用或与长效β-内酰胺类药物 (LABA) 联合使用，而长效毒蕈碱拮抗剂是 COPD 的一线治疗药物。这些特殊的治疗组合导致先进便携式雾化器的成本增加。 Pubmed Central 于 2020 年 9 月发表的一项研究评估了静脉注射甲基泼尼松龙与雾化布地奈德在治疗慢性阻塞性肺病急性加重期 (AECOPD) 的实际成本效益，并得出结论：对于中国 AECOPD 患者，雾化布地奈德与静脉注射甲基泼尼松龙相比并非一种成本效益更高的选择。因此，缺乏早期诊断以及雾化治疗的高昂费用是市场成长的重大障碍。

策略洞察报告细分与范围：「2031年全球雾化器市场分析」是一项全面的研究，重点关注全球市场动态，以识别关键驱动因素、未来趋势和获利机会，从而帮助精准定位主要收入来源。该报告旨在提供市场概览，并按类型、应用程式和最终用户进行详细细分。雾化器市场报告的范围包括北美（美国、加拿大和墨西哥）、欧洲（西班牙、英国、德国、法国、义大利和欧洲其他地区）、亚太地区（韩国、中国、印度、日本、澳洲和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲其他地区）。

細項分析：市场依类型分为喷射雾化器、超音波雾化器和网状雾化器。喷射雾化器在2022年占据了最大的市场。预计网状雾化器在2023-2031年期间的复合年增长率最高。喷射雾化器是一种经济高效且使用者友好的设备，以气雾剂形式输送药物。它们设计为一次性使用，无需灭菌，并最大限度地降低了污染风险。喷射雾化器通常用于机械通气。这些雾化器在治疗慢性呼吸疾病 (CRD) 方面的各种应用正在推动预测期内喷射雾化器市场的成长。

根据应用，市场分为 COPD、气喘、囊性纤维化等。预计 2023 年 COPD 领域将占据雾化器市场的最大份额，而气喘领域预计在 2023-2031 年期间的复合年增长率最高。 COPD 是一种慢性发炎性肺部疾病，会阻碍肺部气流，症状包括呼吸困难、咳嗽、产生黏液和喘息。它主要是由长期接触香烟烟雾等刺激物引起的。 COPD 患者罹患心臟病、肺癌和其他健康问题的风险更高。根据世界卫生组织 (WHO) 的数据，COPD 是全球第三大死因。随着呼吸系统疾病负担的增加，对吸入疗法的需求也增加。此外，向家庭护理治疗的转变正在促进手持雾化器在治疗 COPD 和气喘的使用。

根据最终用户，雾化器市场分为医院和诊所、急诊中心和家庭护理场所。医院和诊所领域在2023年占据了最大的市场份额，并且由于各种类型的雾化器在医疗领域的普及以及这些设备在医院环境中的日益普及，预计在2023年至2030年期间将实现最高的复合年增长率。

区域展望：2023年，北美占据了雾化器市场的最大份额，其中美国位居榜首，加拿大紧随其后，原因是该地区慢性阻塞性肺病 (COPD) 和气喘的盛行率不断上升。根据默沙东 (MSD) 诊疗手册的一篇文章，约有1600万人患有慢性阻塞性肺病 (COPD)，这是一种主要的死亡原因，每年在美国夺走超过15万人的生命。推动北美雾化器市场成长的其他因素包括先进医疗设备的引入、医疗支出的增加以及欧姆龙医疗 (OMRON Healthcare)、BD 和 GE 医疗等主要市场参与者在该地区的存在。

雾化器市场报告范围产业发展与未来机会：根据公司新闻稿，全球雾化器市场主要参与者采取的几项措施包括：

2021 年 12 月，西普拉有限公司 (Cipla Limited) 启动了一项计划，利用其在整个护理过程中的广泛影响力以及广泛的药物-设备组合和治疗方法，提高印度各地农村初级卫生保健中心获得雾化治疗急性哮喘的机会。 2021 年 3 月，PARI Pharma GmbH 推出了其 LAMIRA 雾化器系统，该系统获准在日本销售 ARIKAYCE（阿米卡星脂质体吸入混悬液）。该系统采用基于 eFlow 技术的先进气雾剂输送技术，并配有一个可容纳 8.4 毫升全剂量药物的定製药物储液器。 2021 年 3 月，欧姆龙医疗公司 (OMRON Healthcare, Inc.) 与美国气喘和过敏基金会 (AAFA) 合作，提供医疗级雾化器，以支持 AAFA 的宣传和计划，旨在提高气喘社区中最脆弱成员的意识。竞争格局与主要公司：雾化器市场报告中介绍的知名公司包括欧姆龙医疗公司 (OMRON Healthcare, Inc.)；荷兰皇家飞利浦公司 (Koninklijke Philips NV)、PARI GmbH、Vectura Group Ltd、Drive DeVilbiss International、Briggs Healthcare、GF Health Products Inc.、GE Healthcare Healthcare、Axtaner)。这些公司专注于开发新技术、改进现有产品并拓展地理范围，以满足日益增长的全球消费者需求。

目录

第一章：简介

第二章：执行摘要

• 关键见解
• 市场吸引力分析

第三章：研究方法

第四章：雾化器市场格局

• 概述
• PEST分析
• 生态系分析
  • 价值链中的供应商列表

第五章：雾化器市场－关键市场动态

• 关键市场驱动因素
• 主要市场限制因素
• 关键市场机会
• 未来趋势
• 驱动因素和限制因素的影响分析

第六章：雾化器市场 - 全球市场分析

• 雾化器 - 全球市场概览
• 雾化器－全球市场及2030年预测

第七章：雾化器市场-收入分析-按类型，2020-2030

• 概述
• 喷射雾化器
• 超音波雾化器
• 网状雾化器

第 8 章：雾化器市场 - 收入分析 - 按应用，2020-2030 年

• 概述
• 慢性阻塞性肺病
• 气喘
• 囊肿纤维化
• 其他的

第 9 章：雾化器市场 - 收入分析 - 按最终用户，2020-2030 年

• 概述
• 医院和诊所
• 急诊中心
• 居家照护环境

第 10 章：雾化器市场 - 收入分析，2020-2030 - 地理分析

• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 英国
  • 欧洲其他地区
• 亚太
  • 澳洲
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
• 南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区

第 11 章：产业格局

• 併购
• 协议、合作、合资企业
• 新产品发布
• 扩张和其他策略发展

第 12 章：竞争格局

• 关键参与者的热图分析
• 公司定位与集中度

第 13 章：雾化器市场 - 主要公司简介

• GE Healthcare
• Agilent Technologies, Inc.
• Koninklijke Philips N.V.
• Drive DeVilbiss International
• Omron Healthcare, Inc.
• Vectura Group Ltd
• PARI Medical Holding GmbH
• Trudell Medical International
• Terumo Corporation
• GF Health Products

第 14 章：附录

The nebulizers market was valued at US$ 866.46 million in 2024 and is projected to reach US$ 1315.57 million by 2031; it is anticipated to achieve a CAGR of 6.2% during 2025-2031.

Market Insights and Analyst View:The forecast for the nebulizers market is based on insights gathered from various secondary and primary research sources.

A nebulizer is a device designed to administer medications that assist in managing respiratory issues such as wheezing and to help clear lung secretions. It transforms liquid medication into fine mist droplets, which are inhaled through a mask or mouthpiece, allowing the medicine to enter the lungs directly. Unlike other inhalers, nebulizers utilize an air compressor powered by electricity from a wall outlet.

Drivers and Restraints Affecting Nebulizers Market Growth

In recent years, home healthcare devices have gained popularity due to technological advancements and product miniaturization. This trend has led to an increased adoption of home healthcare devices. Furthermore, the rising elderly population, the high prevalence of chronic respiratory diseases (CRD), and escalating healthcare costs have contributed to a growing preference for home care treatments. Home healthcare offers a cost-effective alternative to expensive hospital stays, thanks to the availability of compact, portable, and user-friendly nebulizers that are well-suited for home use, along with technological innovations aimed at reducing noise and enhancing functionality. Additionally, a variety of medications are available in nebulized forms, including long-acting beta2-agonists (LABAs), long-acting muscarinic receptor antagonists, steroids, antibiotics, and mucolytics. Recent product launches for home use include:

In January 2023, Synergy Life Science, Inc. introduced Nebi, a compact nebulizer powered by batteries suitable for various applications.In July 2021, HCmed Innovations received FDA approval for the Pulmogine Vibrating Mesh Nebulizer, a portable and user-friendly device ideal for patients needing inhalation therapy.In June 2020, Respira Technologies, Inc. launched its RespiRx drug delivery device platform, an ultra-portable handheld vibrating mesh nebulizer (VMN) designed for local and systemic treatment of various conditions, including asthma and COPD.These advancements have broadened the application of nebulizers from acute care settings in clinics and hospitals to home care environments.

However, several factors hinder the growth of the nebulizers market, including a lack of community awareness and understanding of asthma, limited access to healthcare, overburdened healthcare systems, insufficient diagnostic testing (such as spirometry), inadequate training for healthcare providers, and the non-implementation of asthma management guidelines. These issues contribute to the underdiagnosis of asthma, which can lead to poor clinical outcomes for patients using inappropriate medications for their conditions, ultimately expected to impede market growth. Despite the rising global prevalence of asthma, there is a notable reluctance to accept conventional therapies, as many individuals prefer ayurvedic and homemade remedies. Treatment guidelines for asthma and chronic obstructive pulmonary disease (COPD) have evolved significantly, with inhaled corticosteroids (ICSs) being the first-line treatment for asthma, either alone or in combination with LABAs, while long-acting muscarinic antagonists are the first-line treatment for COPD. Such specific treatment combinations have resulted in increased costs for advanced and portable nebulizers. A study published in September 2020 by Pubmed Central evaluated the cost-effectiveness of intravenous methylprednisolone versus nebulized budesonide for treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a practical setting, concluding that nebulized budesonide is not a cost-effective option compared to intravenous methylprednisolone for AECOPD patients in China. Consequently, the lack of early diagnosis and the high costs associated with nebulizing therapy are significant barriers to market growth.

Strategic Insights

Report Segmentation and Scope:The "Global nebulizers market analysis to 2031" is a comprehensive study focusing on global market dynamics to identify key driving factors, future trends, and lucrative opportunities that will help pinpoint major revenue pockets. The report aims to provide an overview of the market with detailed segmentation by type, application, and end-user. The scope of the nebulizers market report includes North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The market is categorized by type into jet nebulizers, ultrasonic nebulizers, and mesh nebulizers. The jet nebulizers segment accounted for the largest market share in 2022. The Mesh Nebulizers segment is expected to exhibit the highest CAGR during 2023-2031. Jet nebulizers are cost-effective and user-friendly devices that deliver medication in aerosol form. They are designed for single-use, eliminating the need for sterilization and minimizing contamination risks. Jet nebulizers are commonly utilized during mechanical ventilation. The various applications of these nebulizers in treating CRD are driving the growth of the jet nebulizers market during the forecast period.

By application, the market is segmented into COPD, asthma, cystic fibrosis, and others. The COPD segment is projected to hold the largest share of the nebulizer market in 2023, while the asthma segment is expected to grow at the highest CAGR during 2023-2031. COPD is a chronic inflammatory lung disease that obstructs airflow from the lungs, with symptoms including difficulty breathing, coughing, mucus production, and wheezing. It is primarily caused by long-term exposure to irritants such as cigarette smoke. Individuals with COPD are at a higher risk of developing heart disease, lung cancer, and other health issues. According to the World Health Organization (WHO), COPD is the third leading cause of death worldwide. As the burden of respiratory diseases increases, so does the demand for inhalation therapies. Additionally, the shift towards home care treatments is boosting the use of handheld nebulizers for managing COPD and asthma.

Based on end-user, the nebulizers market is divided into hospitals and clinics, emergency centers, and home care settings. The hospitals and clinics segment held the largest market share in 2023 and is anticipated to register the highest CAGR from 2023 to 2030 due to the medical availability of various nebulizer types and the growing adoption of these devices in hospital environments.

Regional Outlook:North America accounted for the largest share of the nebulizer market in 2023, with the US leading this region, followed by Canada, due to the rising prevalence of COPD and asthma among the population. According to an article from Merck Sharp & Dohme (MSD) Manual, approximately 16 million individuals suffer from COPD, which is a leading cause of death, claiming over 150,000 lives annually in the US. Other factors driving the growth of the nebulizers market in North America include the introduction of advanced healthcare equipment, increasing healthcare expenditures, and the presence of major market players such as OMRON Healthcare, BD, and GE Healthcare in the region.

Nebulizers Market Report Scope

Industry Developments and Future Opportunities:According to company press releases, several initiatives undertaken by key players in the global nebulizers market include:

In December 2021, Cipla Limited launched an initiative to enhance access to nebulization therapy for managing acute asthma in rural primary healthcare centers across India, leveraging its extensive presence throughout the care continuum and a wide range of drug-device combinations and treatments.

In March 2021, PARI Pharma GmbH introduced its LAMIRA Nebulizer System, authorized to deliver ARIKAYCE (amikacin liposome inhalation suspension) in Japan. This system utilizes advanced aerosol delivery technology based on eFlow Technology and features a customized medication reservoir capable of holding a full dose of 8.4 ml.

In March 2021, OMRON Healthcare, Inc. collaborated with the Asthma and Allergy Foundation of America (AAFA) to provide medical-grade nebulizers to support AAFA's advocacy and initiatives aimed at raising awareness for the most vulnerable members of the asthma community.

Competitive Landscape and Key Companies:Prominent companies profiled in the nebulizers market report include OMRON Healthcare, Inc.; Koninklijke Philips N.V.; PARI GmbH; Vectura Group Ltd; Drive DeVilbiss International; Briggs Healthcare; GF Health Products, Inc.; GE Healthcare; Agilent Technologies, Inc.; Terumo Corporation; and Trudell Medical International. These companies are focused on developing new technologies, enhancing existing products, and expanding geographically to meet the growing global consumer demand.

Table Of Contents

1. Introduction

• 1.1 Scope of the Study
• 1.2 Market Definition, Assumptions and Limitations
• 1.3 Market Segmentation

2. Executive Summary

• 2.1 Key Insights
• 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Nebulizers Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
• 4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Nebulizers Market - Key Market Dynamics

• 5.1 Key Market Drivers
• 5.2 Key Market Restraints
• 5.3 Key Market Opportunities
• 5.4 Future Trends
• 5.5 Impact Analysis of Drivers and Restraints

6. Nebulizers Market - Global Market Analysis

• 6.1 Nebulizers - Global Market Overview
• 6.2 Nebulizers - Global Market and Forecast to 2030

7. Nebulizers Market - Revenue Analysis (USD Million) - By Type, 2020-2030

• 7.1 Overview
• 7.2 Jet Nebulizers
• 7.3 Ultrasonic Nebulizers
• 7.4 Mesh Nebulizers

8. Nebulizers Market - Revenue Analysis (USD Million) - By Application , 2020-2030

• 8.1 Overview
• 8.2 COPD
• 8.3 Asthma
• 8.4 Cystic Fibrosis
• 8.5 Others

9. Nebulizers Market - Revenue Analysis (USD Million) - By End-User, 2020-2030

• 9.1 Overview
• 9.2 Hospitals and Clinics
• 9.3 Emergency Center
• 9.4 Home Care Setting

10. Nebulizers Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

• 10.1 North America
  • 10.1.1 North America Nebulizers Market Overview
  • 10.1.2 North America Nebulizers Market Revenue and Forecasts to 2030
  • 10.1.3 North America Nebulizers Market Revenue and Forecasts and Analysis - By Type
  • 10.1.4 North America Nebulizers Market Revenue and Forecasts and Analysis - By Application
  • 10.1.5 North America Nebulizers Market Revenue and Forecasts and Analysis - By End-User
  • 10.1.6 North America Nebulizers Market Revenue and Forecasts and Analysis - By Countries
    • 10.1.6.1 United States Nebulizers Market
      • 10.1.6.1.1 United States Nebulizers Market, by Type
      • 10.1.6.1.2 United States Nebulizers Market, by Application
      • 10.1.6.1.3 United States Nebulizers Market, by End-User
    • 10.1.6.2 Canada Nebulizers Market
      • 10.1.6.2.1 Canada Nebulizers Market, by Type
      • 10.1.6.2.2 Canada Nebulizers Market, by Application
      • 10.1.6.2.3 Canada Nebulizers Market, by End-User
    • 10.1.6.3 Mexico Nebulizers Market
      • 10.1.6.3.1 Mexico Nebulizers Market, by Type
      • 10.1.6.3.2 Mexico Nebulizers Market, by Application
      • 10.1.6.3.3 Mexico Nebulizers Market, by End-User
• 10.2 Europe
  • 10.2.1 Germany
  • 10.2.2 France
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Rest of Europe
• 10.3 Asia-Pacific
  • 10.3.1 Australia
  • 10.3.2 China
  • 10.3.3 India
  • 10.3.4 Japan
  • 10.3.5 South Korea
  • 10.3.6 Rest of Asia-Pacific
• 10.4 Middle East and Africa
  • 10.4.1 South Africa
  • 10.4.2 Saudi Arabia
  • 10.4.3 U.A.E
  • 10.4.4 Rest of Middle East and Africa
• 10.5 South and Central America
  • 10.5.1 Brazil
  • 10.5.2 Argentina
  • 10.5.3 Rest of South and Central America

11. Industry Landscape

• 11.1 Mergers and Acquisitions
• 11.2 Agreements, Collaborations, Joint Ventures
• 11.3 New Product Launches
• 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

• 12.1 Heat Map Analysis by Key Players
• 12.2 Company Positioning and Concentration

13. Nebulizers Market - Key Company Profiles

• 13.1 GE Healthcare
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
• 13.2 Agilent Technologies, Inc.
• 13.3 Koninklijke Philips N.V.
• 13.4 Drive DeVilbiss International
• 13.5 Omron Healthcare, Inc.
• 13.6 Vectura Group Ltd
• 13.7 PARI Medical Holding GmbH
• 13.8 Trudell Medical International
• 13.9 Terumo Corporation
• 13.10 GF Health Products

14. Appendix

• 14.1 Glossary
• 14.2 About The Insight Partners
• 14.3 Market Intelligence Cloud